VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that during the months of May and June the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the only approved cell therapy in Europe, and of the company's innovative proprietary allogeneic stem cell platform with programs in Phase I, II, and III for a range of inflammatory and autoimmune diseases.
May 15-16
BioEquity, Marriott Hotel, Frankfurt, Germany
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, May 15, 16:00-16:25
Room: Level 1, Room Gold 1
May 21-23
World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza, London, UK
Presenter: Eduardo Bravo, CEO
Date & time: Monday, May 21, 15:25 -15:50
Title: Cell Therapy & Regenerative Medicine - Progressing into phase III with an orphan indication
May 24
Knowledge for Growth, ICC Ghent, Belgium
Presenter: Eduardo Bravo, CEO
Time: 11:30
Keynote speech - Advanced therapies: this time it is for real
June 5-8
18th International Stem Cell Therapy Sociey Annual Meeting, Sheraton Seattle, WA, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: June 7, 13:45-15:15
Title: Plenary Session 4 - Regenerative Medicine and Positioning for Commercial Success - Lessons from the commercial roll out of ChondroCelect in Europe
June 18-21
BIO International Convention, Boston Convention & Exhibition Center, MA, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: June 20, 15:00-15:45
Title: Stem Cell Therapies...Fact or Fiction?
June 23
VFB Biotech Congres, Leuven, Belgium
Location: Imec, Kapeldreef 75, Leuven
Presenter: Gil Beyen, Chief Business Officer
Time: 11am
June 23
Dag van de Biotechnologie, Leuven, Belgium
Location: TiGenix headquarters, Leuven
Event: Open day event throughout Flanders for all biotech companies & academic labs
Time: 10am-5pm
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.
Source: TiGeniX
Bookmark this:
